The GSK oncology products it has sold on to Novartis were worth approximately $2 billion in 2014, having posted a growth of around 32 per cent compared to the previous year. The drugs include ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

"This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products," GSK's Chief ...

But oncology medicines form a small share of ... despite existing approved products.' GSK shares were 0.8 per cent lower at 1,339p on Monday morning and have still fallen by around 15 per cent ...

1). The insights they have provided through their partnership in pan-oncology and disease-specific patient councils are reflected in the design of clinical trials and in building GSK’s pipeline ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

The acquisition also builds on GSK’s recent oncology-focused investments such as the 2022 purchase of Sierra Oncology for $1.9bn. In the announcement accompanying the acquisition, GSK's chief ...